GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (FRA:9OF) » Definitions » Research & Development

BioRestorative Therapies (FRA:9OF) Research & Development : €3.62 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. BioRestorative Therapies's Research & Development for the three months ended in Jun. 2024 was €1.20 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was €3.62 Mil.

BioRestorative Therapies Research & Development Historical Data

The historical data trend for BioRestorative Therapies's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioRestorative Therapies Research & Development Chart

BioRestorative Therapies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.55 0.72 0.65 3.32 3.70

BioRestorative Therapies Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 0.82 0.62 0.97 1.20

BioRestorative Therapies Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioRestorative Therapies  (FRA:9OF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

BioRestorative Therapies Research & Development Related Terms

Thank you for viewing the detailed overview of BioRestorative Therapies's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

BioRestorative Therapies Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (FRA:9OF) » Definitions » Research & Development
Comparable Companies
FBRX ENZN SLXN GLYC KPRX VIRX KTRA JAGX PMCB IKT OCSE:NOVO B REGN VRTX ASX:CSL XKRX:207940 ALNY XBRU:UCB XKRX:068270 MRNA XBRU:ARGX
Traded in Other Exchanges
BRTX:USA 9OF:Germany
Address
40 Marcus Drive, Suite One, Melville, NY, USA, 11747
Website
https://www.biorestorative.com
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

BioRestorative Therapies Headlines

No Headlines